On 16 August 2023, the Health Sciences Authority issued two retail-level recalls for batches of Apo-Amitriptyline and Apo-Acyclovir tablets. The recalls were initiated after impurities at levels above acceptable standards were detected.
Est. reading time: 2 minutes